Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

ImageReady(TM) MR Conditional Pacing System Clinical Study (SAMURAI)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boston Scientific Corporation
ClinicalTrials.gov Identifier:
NCT01781078
First received: January 25, 2013
Last updated: July 28, 2014
Last verified: July 2014

January 25, 2013
July 28, 2014
February 2013
October 2014   (final data collection date for primary outcome measure)
  • Proportion of participants without MR scan-related complications [ Time Frame: MRI Visit + 1 Month ] [ Designated as safety issue: Yes ]
    The primary safety endpoint for SAMURAI will be assessed for all subjects randomized to the MRI Group who undergo any portion of the MRI scan sequences. Safety will be confirmed by evaluating the MRI scan-related Complication-free rate (CFR) between the MR Scan and the MRI Visit + 1 Month Visit.
  • Change in pacing threshold from pre-MRI scan/ Control Group Visit to MRI + 1 Month Visit [ Time Frame: MRI + 1 Month Visit ] [ Designated as safety issue: No ]
    The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to RF field-induced heating, which in turn may cause elevated pacing thresholds. Primary Effectiveness Endpoint 1 will evaluate any chronic effects from lead heating that will be seen through increased pacing threshold at the MRI Visit + 1 Month follow-up.
  • Change in sensed amplitude from pre-MRI scan/ Control Group Visit to MRI + 1 Month Visit [ Time Frame: MRI + 1 Month Visit ] [ Designated as safety issue: No ]
    The MRI scan can result in damage to cardiac tissue surrounding lead electrodes due to Radiofrequency (RF) field-induced heating. Primary Effectiveness Endpoint 2 will evaluate any chronic effects from lead heating that will be seen through decreased sensed amplitude at the MRI Visit + 1 Month follow-up.
Same as current
Complete list of historical versions of study NCT01781078 on ClinicalTrials.gov Archive Site
Proportion of participants without ImageReady System-related complications [ Time Frame: 3 months post implant ] [ Designated as safety issue: Yes ]
Overall safety of the ImageReady System will be confirmed by evaluating system-related complications that occur from system implant through 3 months post implant for subjects in both the MRI and Control groups.
Same as current
Not Provided
Not Provided
 
ImageReady(TM) MR Conditional Pacing System Clinical Study
ImageReady(TM) MR Conditional Pacing System Clinical Study

The objective of the SAMURAI Clinical Study is to collect data to confirm the safety, performance and effectiveness of the ImageReady System for use in the Magnetic Resonance Imaging (MRI) environment when used in accordance with the Conditions of Use included in the Boston Scientific MRI Technical Guide

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Bradycardia
  • Sinus Node Dysfunction
  • Radiation: MRI
    The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
    Other Names:
    • MRI
    • MR Scan
  • Device: ImageReady System implant
    Pacemaker and lead(s) implant
    Other Names:
    • Single chamber pacemaker implant
    • Dual chamber pacemaker implant
    • Pace/ Sense pacemaker lead implant
  • Experimental: MRI Group
    Those subjects randomized to the MRI Group will undergo a study-specific MRI scan 6-9 weeks post-implant.
    Interventions:
    • Radiation: MRI
    • Device: ImageReady System implant
  • Experimental: Control Group
    Those subjects randomized to the Control Group will not undergo s study-specific MRI scan. All follow-up time requirements are the same for the two groups.
    Intervention: Device: ImageReady System implant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
363
February 2019
October 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject must have the ImageReady System as their initial (de novo) pacing system implant
  • Subject has a Class I or II indication for implantation of a single or dual chamber pacemaker according to the ACC/AHA/HRS, or ESC guidelines, as appropriate per geography
  • Subject is able and willing to undergo an MRI scan without intravenous sedation
  • Subject is willing and capable of providing informed consent (which can include the use of a legally authorized representative (LAR) for documentation of informed consent) and participating in all testing/ visits associated with this clinical study at an approved clinical study center and at the intervals defined by this protocol
  • Subject is age 18 or above, or of legal age to give informed consent specific to state and national law

Exclusion Criteria:

  • Subject has or has had any pacing or ICD system implants
  • Subject has any MR Unsafe implants or devices with an unknown MR status, including MR Unsafe sternal wires, neurostimulators, biostimulator, metals or alloys, per labeling of each implant
  • Subject has any MR Conditional implants or devices that impact the ability to conduct this protocol
  • Subject needs or will need another MR scan within 14 weeks of system implant, other than that required by the SAMURAI Study
  • Subject has a known or suspected sensitivity to dexamethasone acetate (DXA)
  • Subject has a mechanical tricuspid heart valve
  • Subject is enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries* that are not in conflict and do not affect the following:

    • Schedule of procedures for the SAMURAI Study (i.e. should not cause additional or missed visits);
    • SAMURAI Study outcome (i.e. involve medications that could affect pacing thresholds);
    • Conduct of the SAMURAI Study per GCP/ ISO 14155:2011/ local regulations
  • Subjects with documented permanent or persistent AF where the physician intends to implant a dual chamber pulse generator (single chamber VVIR pulse generators are acceptable)
  • Subject is currently on the active heart transplant list
  • Subject has documented life expectancy of less than 12 months
  • Women of childbearing potential who are or might be pregnant at the time of study enrollment or ImageReady MR Conditional Pacing System implant (method of assessment upon physician's discretion)
  • Subjects currently requiring dialysis
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Canada,   China,   Israel,   Malaysia,   Singapore
 
NCT01781078
BSC-CDM00047737
Yes
Boston Scientific Corporation
Boston Scientific Corporation
Not Provided
Principal Investigator: Ronald Berger, MD, PhD Johns Hopkins Hospital, Carnegie 530, 600 N. Wolfe St, Baltimore, MD 21287
Boston Scientific Corporation
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP